Association of long QT syndrome loci and cardiac events among patients treated with β-blockers

JAMA

Volumn 292, Issue 11, 2004, Pages 1341-1344

  Priori, Silvia G ^a,c   Napolitano, Carlo ^a   Schwartz, Peter J ^b   Grillo, Massimiliano ^a   Bloise, Raffaella ^a   Ronchetti, Elena ^a   Moncalvo, Cinzia ^a   Tulipani, Chiara ^a   Veia, Alessia ^a   Bottelli, Georgia ^a   Nastoli, Janni ^a  

^a IRCCS   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NADOLOL; PROPRANOLOL; ERG1 POTASSIUM CHANNEL; KCNH2 PROTEIN, HUMAN; KCNQ1 PROTEIN, HUMAN; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNQ; POTASSIUM CHANNEL KCNQ1; SODIUM CHANNEL; VOLTAGE GATED NA+ CHANNEL NA(V)1.5A; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE-GATED NA+ CHANNEL NA(V)1.5A;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENOTYPE; HEART ARREST; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; QT INTERVAL; SUDDEN DEATH; SYNCOPE; TORSADE DES POINTES; DISEASE COURSE; GENETICS; PATHOPHYSIOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; DISEASE PROGRESSION; ETHER-A-GO-GO POTASSIUM CHANNELS; GENOTYPE; HUMANS; KCNQ POTASSIUM CHANNELS; KCNQ1 POTASSIUM CHANNEL; LONG QT SYNDROME; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; SODIUM CHANNELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4544387969     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.11.1341     Document Type: Article

References (10)

1. Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare dell'età pediatrica. Clin Pediatr. 1963;45:656-683.
2. Ward OC. A new familial cardiac syndrome in children. J Irish Med Assoc. 1964;54:103-106.
3. Schwarte PJ, Priori SG, Napolitano C. The long QT syndrome. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 2000:597-615.
4. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J. 2001;22:1374-1450.
5. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long QT syndrome. Circulation. 2004;109:1826-1833.
6. Groh WJ, Silka MJ, Oliver RP, Halperin BD, McAnulty JH, Kron J. Use of implantable cardioverterdefibrillator in the congenital long QT syndrome. Am J Cardiol. 1996;78:703-706.
7. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101:616-623.
8. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long QT syndrome: gene-specific triggers for life threatening arrhythmias. Circulation. 2001;103:89-95.
9. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 2001;104:569-580.
10. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long QT syndrome. N Engl J Med. 2003;348:1866-1874.